FDA panel considers a first-of-its-kind flu vaccine using mRNA technology

U.S. wellness advisers are debating a caller benignant of flu vaccine

WASHINGTON -- U.S. wellness advisers are debating a caller benignant of flu vaccine Thursday, the archetypal made with the aforesaid mRNA exertion that was cardinal to ending the COVID-19 pandemic.

Moderna is seeking Food and Drug Administration support of its caller shot, dubbed mFlusiva, arsenic an enactment for radical 50 and older. The FDA advisory committee gathering is simply a measurement toward a last determination up of the wintertime flu season.

Tens of thousands of Americans dice from influenza each year, and older adults are among the astir vulnerable. There are assorted types of flu vaccines already disposable successful the U.S., including 3 specifically recommended for radical 65 and older. But vaccines made with the Nobel Prize-winning mRNA exertion are faster to manufacture than different types — thing experts accidental mightiness assistance if the shape-shifting flu microorganism mutates successful a mode that requires abruptly brewing caller doses to match.

In a survey of 40,000 radical property 50 and older, Moderna’s mRNA vaccine reduced flu cases by astir 27% compared to those fixed different routinely utilized vaccine brand. Ahead of the meeting, FDA published a favorable reappraisal of that information and reported nary information concerns.

Moderna is seeking afloat support for the vaccine’s usage successful the 50- to 64-year-old colonisation — on with authorization for usage successful those 65 and older portion it conducts further testing.

Earlier this year, Moderna’s information was astatine the halfway of a highly antithetic nationalist quality arsenic a then-top FDA authoritative blocked the company’s exertion for its first-of-its-kind shot.

The embattled vaccine main astatine the time, Dr. Vinay Prasad, said the institution should person compared its changeable to a high-dose flu vaccine recommended for seniors alternatively than a standard-dose brand. It was a motion of FDA’s heightened vaccine scrutiny nether Health Secretary Robert F. Kennedy Jr.

Moderna challenged that decision, noting that FDA unit had approved that main study’s plan and citing a separate, smaller survey comparing the mRNA changeable with a high-dose vaccine for seniors. Days aft the spat, the FDA accepted Moderna’s application.

The adept sheet besides volition measure that smaller study, which recovered Moderna’s changeable generated flu-fighting antibodies likewise to a high-dose elder shot. The FDA’s archetypal reappraisal noted the caller vaccine lacks information connected precise frail older adults and those with anemic immune systems.

____

The Associated Press Health and Science Department receives enactment from the Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely liable for each content.

Sponsored Content by Taboola